Madhuri Roy

Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Cooley advised the underwriters in the upsized $345.1 million initial public offering of Apogee Therapeutics, a biotechnology company.

Cooley advised Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases, on its definitive agreement to sell to Pfizer for $6.7 billion. Partners Jamie Leigh, Kevin Cooper and Steve Przesmicki led the Cooley team advising Arena.

Cooley advised the underwriters on DICE Therapeutics’ $234.6 million initial public offering of 13,800,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. BofA Securities, Inc., SVB Leerink LLC and Evercore Group L.L.C. acted as the lead book-running managers for the offering. DICE Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol “DICE,” is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Partners Charlie Kim, Christina Roupas, Kristin VanderPas and Courtney Tygesson led the Cooley team.

Cooley advised the underwriters on Erasca’s $345 million initial public offering of 21,562,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering. Erasca, whose securities now trade on the Nasdaq Global Select Market under the symbol ERAS, is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Sean Clayton and Kristin VanderPas led the Cooley team.